Added to YB: 2025-07-10
Pitch date: 2025-07-04
VIVS [bullish]
VivoSim Labs, Inc.
+25.02%
current return
Author Info
No bio for this author
Company Info
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine.
Market Cap
$4.6M
Pitch Price
$1.58
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.49
P/E
-1.04
EV/Sales
-40.06
Sector
Biotechnology
Category
value
Weird Shit Investing 2025 - VivoSim Labs
VIVS: Synthetic biology co trading below cash value ($3.99M mkt cap) with Eli Lilly deal. Organoid tech predicts drug toxicity. $250-750K revenue expected FY26 + potential $5M milestone. Tiny float (2.57M shares) creates takeover potential. Similar private peers valued 10-40x higher. Asymmetric upside with pharma validation.
Read full article (1 min)